Intellectual Asset Management Recognizes Foley Attorneys in 2021 Patent 1000 Guide
July 15, 2021
Intellectual Asset Management
Intellectual Asset Management (IAM) has recognized 15 Foley attorneys in the 10th edition of its Patent 1000 – The World’s Leading Patent Professionals guide. Additionally, the firm was recognized for offices and practices, including the District of Columbia (prosecution), Milwaukee and Detroit.
The Foley attorneys recognized include:
- Scott Anderson, prosecution
- Courtenay Brinckerhoff, prosecution
- Jeffrey Costakos, litigation
- Jeanne Gills, litigation
- Jeffrey Gundersen, prosecution
- John Lanza, prosecution
- Matthew Lowrie, litigation
- Stephen Maebius, prosecution, transactions
- Christopher McKenna, prosecution
- George Quillin, prosecution
- Michele Simkin, prosecution
- Gary Solomon, prosecution
- Eric Sophir, prosecution
- Marcus Sprow, prosecution
- Joseph Ziebert, prosecution
The Patent 1000 – The World’s Leading Patent Professionals guide is compiled by a team of researchers from IAM magazine based on more than 1,800 interviews with private practice and in-house professionals regarding the full range of patent services. For more information about IAM and Patent 1000, please visit their website.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."